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Purpose: To investigate the glycated albumin (GA) introduction implications, as an add-on 
strategy to traditional glycemic control (Hb1Ac and fasting plasma glucose – FPG) instru-
ments, considering insulin-naïve individuals with type 2 diabetes mellitus (T2DM), treated 
with oral therapies.
Methods: A Health Technology Assessment was conducted in Italy, as a multi-dimensional 
approach useful to validate any innovative technology. The HTA dimensions, derived from 
the EUnetHTA Core Model, were deployed by means of literature evidence, health econom-
ics tools and qualitative questionnaires, filled-in by 15 professionals.
Results: Literature stated that the GA introduction could lead to a higher number of 
individuals achieving therapeutic success after 3 months of therapy (97.0% vs 71.6% without 
GA). From an economic point of view, considering a projection of 1,955,447 T2DM insulin- 
naïve individuals, potentially treated with oral therapy, GA introduction would imply fewer 
individuals requiring a therapy switch (−89.44%), with a 1.06% in costs reduction, on annual 
basis, thus being also the preferable solution from a cost-effectiveness perspective (cost- 
effectiveness value: 237.74 vs 325.53). According to experts opinions, lower perceptions on 
GA emerged with regard to equity aspects (0.13 vs 0.72, p-value>0.05), whereas it would 
improve both individuals (2.17 vs 1.33, p-value=0.000) and caregivers quality of life (1.50 vs 
0.83, p-value=0.000). Even if in the short term, GA required additional investments in 
training courses (−0.80 vs 0.10, p-value = 0.036), in the long run, GA could become the 
preferable technology (0.30 vs 0.01, p-value=0.018) from an organisational perspective.
Conclusion: Adding GA to traditional glycaemic control instruments could improve the 
clinical pathway of individuals with T2DM, leading to economic and organisational advan-
tages for both hospitals and National Healthcare Systems.
Keywords: glycated albumin, type 2 diabetes mellitus, T2DM, Health Technology 
Assessment, economic evaluation, multidimensional approach
Introduction
Diabetes mellitus (DM) is a perfect example of a chronic disease that represents 
a significant burden on individuals and healthcare systems in the European Union 
and beyond, considering both insurance-based and National Healthcare Service 
(NHS)-based healthcare systems. According to the International Diabetes 
Federation, and considering type 2 diabetes mellitus (T2DM), in Europe almost 
60 million people have T2DM and the number is projected to exceed 70 million by 
2045, as more people live longer and grow heavier.1
The primary aim of T2DM individuals care, and consequently of antiglycemic 
oral therapies, is the achievement and the maintenance of glycemia in target, 
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regulating blood glucose, and retaining glycaemia at (or 
below) the percentage of all haemoglobin that is glycated 
considering the target of 7% (53 mmol/mol). Strict gly-
caemic control in individuals with T2DM decreases the 
incidence of diabetic complications, which could deter-
mine the quality of life and prognosis of such chronic 
population.2,3
With regard to T2DM glycaemic control, traditionally, 
glycated haemoglobin (HbA1c), is an important indicator 
for long-term glucose monitoring, representing, together 
with fasting plasma glucose (FPG), the standard panel of 
in vitro diagnostics instruments for this specific setting.4–9 
However, HbA1c may not be suitable for the evaluation of 
short-term variations of glycaemic control because of the 
long lifespan of erythrocyte.4,10,11
Over the last few years, an innovative glycaemic mar-
ker has emerged in clinical practice, which is useful for 
monitoring glycaemic control in T2DM individuals:6 gly-
cated albumin (GA), to be implemented in addition to the 
above-mentioned traditional monitoring instruments 
(HbA1c and FPG), as an add-on strategy. GA, 
a ketoamine formed by non-enzymatic glycation of 
serum albumin, reflects short-term (2–3 weeks) mean gly-
caemic levels.12,13 Furthermore, GA values are not 
affected by changes in erythrocyte lifespan,14 and mea-
surement of GA is not influenced by anaemia or other 
individuals’ clinical conditions or comorbidities (i.e. indi-
viduals with diabetes on dialysis), which could invalidate 
HbA1c measurements, in the diagnosis and monitoring of 
diabetes.15,16
Hence, this assay accurately reflects glycaemic control 
in T2DM individuals, whether their antihyperglycemic 
regimens are stable or being changed to improve control, 
thus also predicting future HbA1c levels, and consequently 
being helpful to clinicians wishing to evaluate early treat-
ment responses or predict deteriorations in glycaemic 
control.17 Despite the importance of this innovative gly-
caemic marker, at present, its use in the Italian clinical 
practice is not yet standardized. Conversely, Asian 
Countries, such as Japan and China, have already utilized 
this innovative glycaemic marker in routine practice, with 
its inclusion in specific country-oriented guidelines and 
recommendations, as well as a consequent specific reim-
bursement tariff development.18–20
Therefore, an in-depth study is needed, particularly in 
the European setting, with a specific focus on Italy, since 
the Italian context represents the second In Vitro 
Diagnostic (IVD) market, after Germany, thus being the 
perfect location to evaluate the potential GA diffusion and 
impacts in both insurance-based and NHS-based health-
care systems.21 This is consistent with the European reg-
ulation on medical devices, reporting that once a product 
has proven its safety, efficacy and quality, it may need to 
go through an evaluation of its value compared with exist-
ing healthcare interventions, before being granted full 
access to markets.22 The governments, both at local and 
central level, would evaluate and consider only those 
innovations that were able to demonstrate their value-for 
money, and cost-effectiveness.23
Beyond these premises, the study aims at defining the 
potential benefits of GA introduction in the Italian clinical 
practice, as an add-on technology to the traditional glycaemic 
monitoring systems (Hb1Ac and FPG), thus creating con-
sensus with regard to its routinely use in monitoring T2DM 
individuals, and answering to the following policy question:
Could GA be considered an appropriate and sustainable 
glycaemic marker to be implemented within the Italian 
NHS, for the adequate monitoring activity of T2DM insu-
lin-naïve individuals? 
This could support the decision-making process of all 
European and international Countries not yet using GA, 
by providing evidence-based information, with regard to 
its effectiveness, safety, efficiency and sustainability.
Methods
A Health Technology Assessment (HTA) was conducted in 
2018–2019, considering the Italian NHS perspective and 
focusing on insulin-naïve individuals affected by T2DM 
diabetes, treated with oral therapies.
Due to the multi-dimensional and multi-disciplinary 
nature of an HTA, several aspects of the medical technol-
ogies were considered, as stated within the EUnetHTA 
Core Model.23 The following dimensions were analysed: 
i) relevance of the health problem; ii) technical description 
of the technologies under assessment; iii) safety; iv) effi-
cacy and effectiveness; v) economic and financial impact; 
vi) equity; vii) legal aspects; viii) social and ethical 
impact; and ix) organisational impact.
A Focus on the Assessment of the 
Dimensions
The above dimensions were deployed considering the fol-
lowing methodological approaches.
a) A systematic literature review was conducted, to 
retrieve the safety and the efficacy profiles of both the 
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traditional instruments and the GA add-on strategy poten-
tial impact, as well as to identify the target population 
eligible to GA use.
The PICO approach (Problem/population, Intervention, 
Comparator and Outcome) for literature retrieval was 
identified:24,25 i) P (population) - insulin-naïve individuals 
affected by T2DM, treated with oral therapies; ii) 
I (intervention) - introduction of GA to be implemented 
with Hb1Ac and FPG; iii) C (comparator) - traditional 
panel of instruments for glycaemic control (Hb1Ac and 
FPG); iv) O (outcome) - clinical effectiveness, in terms of 
rate of individuals achieving therapeutic success after 3 
months of therapy.
Literature evidence came from a systematic search of 
literature databases (PubMed, Embase and Cochrane 
Library), from 2011 up to December 2020, considering 
the following search strategy: “glycosylated serum 
albumin”[Supplementary Concept] OR “glycosylated 
serum albumin”[All Fields] OR “glycated albumin”[All 
Fields]. Besides consistency with the search strategy, the 
defined inclusion criteria were the following: i) number of 
patients enrolled in the study (> 20); ii) journal impact- 
factor (> 1); iii) study design and clarity of the compara-
tive claim. Once identified the papers to be included in the 
HTA, an independent validation of the scientific evidence 
available on the topic was performed, through the CASP 
(Critical Appraisal Skills Programme) checklist, with the 
support of 7 experts (3 methodological experts, 2 diabetol-
ogists and 2 laboratory experts).26
b) Health economics tools have been used for the 
economic evaluation of the clinical pathway and for bud-
get impact analysis. The clinical pathway was defined in 
terms of standard procedures performed by T2DM indivi-
duals, according to structured interviews with 5 clinicians, 
referring to 5 Italian hospitals. A final approval and agree-
ment from the clinicians of reference, in accordance with 
a Delphi approach,27 was retrieved, considering the fol-
lowing items that were mapped. i) Number and typology 
of blood/laboratory exams; ii) number and typology of 
diagnostic procedures; iii) number and typology of dia-
betic visits and other specialist visits; and iv) number and 
typology of self-monitoring of blood glucose. The stan-
dard clinical pathway, related to the implementation of 
only traditional instruments, was carried out and evalu-
ated, comparing the clinical pathway of the individuals 
who have not experienced a therapy switch within a 12- 
month time horizon of treatment and monitoring, and the 
clinical pathway of the individuals who have experienced 
a therapy switch, during the 12-month time horizon of 
treatment and monitoring. It should be noted here that 
the therapeutic switch rate was hypothesized from scien-
tific literature, in terms of diabetic individuals deemed to 
not have an effective response to the current oral therapy, 
since they did not achieve the glycemia in target.28 
Furthermore, the innovative clinical pathway with GA 
introduction, was also hypothesised and accordingly 
valorised, starting from the traditional approach pathway 
analysis, thus defining possible changes in the number of 
blood exams specialist visits or diagnostic procedures. The 
above economic information was evaluated, in accordance 
with outpatients/hospital admission National 
Reimbursement Tariffs, already valid for years 
2020–2021.29
The economic evaluation of the two clinical pathways 
was integrated with a cost-effectiveness analysis and 
a budget impact analysis. On one hand, the cost- 
effectiveness value indicator (CEV), in average terms, 
was determined in order to choose the technology that 
shows a better cost-effectiveness trade-off (calculated as 
cost per T2DM individual divided by the efficacy indica-
tor, in terms of percentage of individuals achieving ther-
apeutic success after 3 months of therapy), for both 
scenarios. On the other hand, the budget impact analysis 
compared the “AS IS” situation (use of only the traditional 
instruments), with the “TO BE” situation (introduction of 
the GA test in addition to the traditional panel of instru-
ments), in order to define the economic sustainability of 
the innovative marker. A 100% replacement rate was 
assumed, for the introduction of the new technology, and 
the number of eligible T2DM individuals was determined, 
based on the Italian epidemiological T2DM prevalence 
rates available in the national evidence.29,30
c) Administration of qualitative questionnaires filled 
out by 15 healthcare T2DM diabetes experts (5 laboratory 
experts, 1 epidemiologist, 5 diabetes clinicians, 2 strategic 
directions, 2 representative of patients associations), repre-
sentative of all the stakeholders across Italy (referring to 
both public and private hospitals) who have specific 
knowledge of the use of GA, because of their involvement 
in experimental studies on the topic.
The qualitative questionnaires were used for examining 
clinicians’ perceptions on equity, social, legal, and organi-
sational aspects, considering a comparative approach of 
the two panels of technology being assessed, in accor-
dance with a 7-item Likert scale ranging from – 3 to +3.31
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All the items used for the deployment of each qualita-
tive dimension, derived from the EUnetHTA Core Model 
issues,23 with specific integrations and modifications, in 
relation with the nature of the technology being assessed.
The above qualitative method was useful to collect 
a wide range of ideas and opinions that individuals carry 
out about issues and topics, as well as divulge viewpoint 
differences among stakeholders’ groups.32–34 Furthermore, 
for under discovered research areas, qualitative methods 
attempt to fill in gaps that are left unexposed by survey- 
based research, as well as literature evidence.35
A Focus on the Statistical Methods
Data were first synthetized, considering descriptive statis-
tics. Statistically significant differences were analyzed, 
using parametric or not parametric tests, depending on 
the normal distribution of the variables investigated.
With regard to the economic dimension, a sensitivity 
analysis was conducted, by means of Bayesian methods, 
useful to provide a complete paradigm for both statistical 
inference and decision making under uncertainty.36,37 
Gamma distributions were accordingly developed, in 
order to verify the robustness of the results, in presence 
of uncertainty factors (clinical pathway cost and CEV 
parameters were analyzed). The probability to have: i) 
any average cost value of the gamma distribution of the 
innovative panel of technology, lower with respect to the 
traditional one, and ii) any average CEV of the gamma 
distribution of the innovative panel of technology, lower 
with respect to the traditional one, was evaluated.
Results
Results from Literature Review
The search for Mesh terms resulted in 612 records. Out of 
them, only 50 were assessed for eligibility. In accordance 
with the above-mentioned search strategy, only 5 
articles13,28,38–41 met the inclusion criteria defined in the 
methodology section, focusing on the specific use of GA 
for T2DM insulin-naïve individuals and comparing GA 
and HbA1c, as presented in the Prisma Flow Chart 
(Supplementary Figure 1). The other 45 articles had dif-
ferent aims, without focusing the attention on efficacy/ 
safety data, but presenting sensibility and specificity infor-
mation, concerning the presence of a strict correlation 
between GA and HbA1c.
Table 1 Economic Evaluation of the Diabetic Individual’s Clinical Pathway Derived from Delhi Approach Implementation
Traditional Instruments – “AS IS” Scenario
Health Expenditure Items Economic Evaluation of an Individual Who 
Has Not Experienced a Therapy Switch 
Within a 12-Month Time Horizon
Economic Evaluation of an Individual Who 
Has Experienced a Therapy Switch Within 
a 12-Month Time Horizon
Economic Value % Economic Value %
Laboratory exams € 68.67 31.89% € 74.08 26.66%
Specialist visits € 55.99 26.00% € 68.59 24.68%
Diagnostic procedures € 18.66 8.67% € 20.01 7.20%
Self-monitoring of blood glucose € 72.00 33.44% € 115.20 41.46%
Annual management medical cost € 215.31 100.00% € 277.88 100.00%
Traditional Instruments + GA – “TO BE” Scenario
Health Expenditure Items Economic Evaluation of an Individual Who 
Has Not Experienced a Therapy Switch 
Within a 12-Month Time Horizon
Economic Evaluation of an Individual Who 
Has Experienced a Therapy Switch Within 
a 12-Month Time Horizon
Economic Value % Economic Value %
Laboratory exams € 79.92 35.27% € 96.70 32.18%
Specialist visits € 55.99 24.71% € 68.59 22.83%
Diagnostic procedures € 18.66 8.24% € 20.01 6.66%
Self-monitoring of blood glucose € 72.00 31.78% € 115.20 38.34%
Annual management medical cost € 226.56 100.00% € 300.50 100.00%
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Literature review stated that the introduction of GA as 
add-on strategy could improve both safety and the efficacy 
profiles, in comparison with the use of only traditional 
monitoring instruments.
From a safety point of view, GA could be a better 
relative risk predictor in the development of diabetes com-
plications compared with using HbA1c alone, considering 
diabetic retinopathy, nephropathy, and cardiovascular 
events development.42–46
From an efficacy point of view, GA would increase 
the number of individuals achieving therapeutic success 
after three months of therapy (97.0% vs 71.6%), - in 
terms of individuals deemed to have effective response 
to oral therapy - with a consequent decrease in people 
with diabetes requiring a therapeutic switch.28 This 
would strengthen the consideration that GA is a useful 
marker for the monitoring activities of diabetes, thus 
being able to determine the effectiveness of treatment 
before initiating or changing medication for individuals 
with diabetes.12,47 Indeed, there may be no discernible 
reduction in the HbA1c level until several weeks after 
starting treatment, which may delay the determination of 
whether the specific therapeutic regimen is effective.28
Results from the Health Economics 
Evaluation
The economic evaluation of the “AS IS” and the “TO BE” 
scenario is detailed in Table 1, thus revealing a statistically 
significant difference between an individual who has not 
experienced a therapy switch within a 12-month time 
horizon and an individual who has experienced a therapy 
switch within a 12-month time horizon, in both scenarios 
(p-value = 0.000).
In the comparison between the weighted average cost, 
considering the therapeutic switch occurrence rate,28 in 
terms of diabetic individuals not achieving an oral 
response therapy, no statistically significant differences 
emerged (€ 233.08 vs € 230.61, p-value > 0.05). 
However, sensitivity analysis reports that the innovative 
clinical pathway panel presented a probability to absorb 
lower economic resources equal to 74.53%, considering 
a 12-month time horizon (Figure 1).
Figure 1 Gamma distributions for costs.
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Table 2 reports that the innovative panel of technology 
could be the preferable solution to be adopted from a cost- 
effectiveness point of view, thus always presenting the 
better trade-off between costs and effectiveness, with 
respects to the traditional instruments (Figure 2).
Whereas a CEA evaluates both costs and outcomes of 
alternative technologies over a specified time horizon, to 
estimate their economic efficiency, a budget impact analy-
sis (BIA) is based on their affordability within a specific 
setting.
Based on the Italian population in 2018 and the dia-
betes prevalence rate, equal to 5.3%,30 3,205,651 Italian 
individuals suffer from T2DM diabetes. Out of them, 61% 
are being treated with oral therapies,31 thus resulting in 
1,955,447 individuals, who could be potential users of the 
new GA glycaemic biomarker.
Given the economic evaluation previously mentioned, 
as well as the percentage of individuals experiencing 
a therapy switch, the GA test introduction would lead to 
fewer individuals requiring a therapy switch (−89.44%), 
with an economic advantage of 1.06% (in a 12-month time 
horizon). The Italian NHS could save € 4,835,985, through 
the proper clinical management of 1,955,447 type 2 dia-
betic insulin-naïve individuals, treated with oral therapy 
(Table 3).
Results from the Qualitative Assessment
The analysis of the qualitative perceptions of the health-
care professionals involved (Table 4) (as already 
explained, considering a 7-item Likert Scale, ranging 










cost, considering the 
therapeutic switch
€ 233.08 € 230.61
Efficacy (Shima et al, 
2014)
71.60% 97.00%
CEV – Cost- 
Effectiveness Value
325.53 237.74
Figure 2 Gamma distributions for cost-effectiveness value.
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from – 3 to + 3), reported that the traditional instruments 
could be considered the preferable technology (0.72 vs 
0.13, p-value > 0.05), from an equity perspective. This 
consideration may be justified by limited accessibility to 
GA (−0.42 vs 1.83, p-value = 0.000), since the innovative 
technology has not yet been used and implemented in the 
Italian laboratories. In contrast, GA could be the preferable 
glycaemic marker, considering the professionals’ percep-
tion on the item “existence of factors limiting the use of 
the technology” (1.33 vs 0.67, p-value = 0.000), covering 
a larger population. In fact, GA is not influenced by 
erythrocyte lifespan, nor by anaemia, or other individuals’ 
clinical conditions, which invalidate HbA1c measure-
ments, in the monitoring of diabetes.12,45,48–50
The introduction of a GA test would improve the 
quality of life of both individuals with diabetes (1.33 vs 
2.17, p-value = 0.000) and caregivers (0.83 vs 1.50, 
p-value = 0.000), since it is related to better glycaemic 
control monitoring and a lower relative risk of developing 
diabetes-related complications and adverse events.
An analysis of the legal implications reported that the 
two technologies under assessment could be considered 
super-imposable in their measurement (p-value > 0.05). 
Additional legal efforts are required regarding the regula-
tion of GA acquisition.
Focusing on the organisational dimension (Table 5), in 
the short term (12 months), the GA test acquired a lower 
score than the comparator, since it needs additional invest-
ments in training courses for all those who are involved in 
the procedure (−0.80 vs 0.10, p-value = 0.036). 
A component that impacts significantly on the organisation 
appeared to be the acquisition of the new technology 
(−0.20 vs 0.00, p-value > 0.05), as well as the updating 
of laboratory equipment currently in use (−0.50 vs 0.00, 
p-value > 0.05), even if no statistically significant differ-
ences emerged. However, the implementation and the 
adoption of GA in clinical practice would allow an 
improvement in the diabetic individuals’ clinical pathway 
(0.90 vs 0.10, p-value = 0.015).
Over a 36-month time-period from market penetration, 
there was a contraction in the above-mentioned draw-
backs. The healthcare professionals, having become com-
petent at using the innovative technology, no longer need 
to attend training courses. In this view, it emerges that the 
innovative technology may be considered the most pre-
ferred alternative from an organisational point of view, 
with an average value of 0.30 (p-value = 0.018).
Discussion
The results of the study generate an interesting scientific 
contribution, thus covering an important knowledge gap, 
regarding the implementation of GA test, in clinical prac-
tice, for glycaemic control in insulin-naïve individuals 
affected by T2DM. This is particularly important, because 
both early diagnosis of diabetes and strict glucose control 
are crucial for preventing or delaying the onset of serious, 
even life-threatening complications.51 In this view, the 
HTA results strengthen this consideration, showing that 
the introduction of GA in addition to the traditional instru-
ments for glycaemic control may be considered a valid 
technological alternative, for the treatment of T2DM peo-
ple with diabetes. As stated in literature evidence, the 
introduction of GA as an add-on technology presents 
advantages in both safety and efficacy profiles, with 
Table 3 Budget Impact Analysis
Traditional Instruments (“AS IS” Scenario) Population Cost
-no switch 1,400,100 € 301,457,308.22
- switch 555,347 € 154,321,073.18
Total Baseline Scenario € 455,778,381.40
Traditional Instruments + GA (“TO BE” 
Scenario)
Population Cost
-no switch 1,896,783 € 433,313,949.72
- switch 58,663 € 17,628,446.14
Total Innovative Scenario € 331,146,644.54
Difference (€) −496,683 -€ 4,835,985.54
Difference (%) −89.44% −1.06%
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a consequent positive impact, concerning both the eco-
nomic and the individual’s perspective.3,28,38–41
Results have demonstrated the feasibility and the sus-
tainability of GA introduction into the clinical practice, 
revealing the need for less investment related to its acqui-
sition. Additional advantages of GA over HbA1c are 
represented by its comparable costs, and by the possibility 
to process the GA test using conventional laboratory clin-
ical chemistry analysers, without additional organisational 
effort and being consistent with literature evidence avail-
able on the topic.51 According to that, the budget impact 
analysis showed that the investment for GA routine 
Table 4 Qualitative Assessment of the Equity, Ethical, Social and Legal Impacts
Equity Impact Traditional Instruments – 
“AS IS” Scenario
Traditional Instruments + GA – 
“TO BE” Scenario
Access to care on local level 1.83 −0.42
Access to care for person with legally protected status 1.75 −0.58
Impact on the hospital waiting list 0.08 0.33
Generation of health migrations phenomena 0.75 1.17
Existence of factors limiting the use of the technology for a group 
of individuals
0.67 1.33
The different willingness to pay among individuals could modify the 
accessibility of the technology
0.08 −1.00
Level of iniquity of the technology 0.58 0.17
Individuals’ Cultural, moral and religious beliefs could modify the 
accessibility of the technology
0.00 0.00
Average value for equity impact 0.72 0.13
Ethical and Social Impact Traditional Instruments – 
“AS IS” Scenario
Traditional Instruments + GA – 
“TO BE” Scenario
Ability of the technology to protect the individuals’ autonomy 1.33 1.75
Protection of human rights 1.58 1.58
Ability of the technology to protect the individuals’ integrity 1.42 1.42
Ability of the technology to protect the individuals’ dignity 1.33 1.33
The use of the technology guarantees the social values and the 
willingness to pay of the individual
0.83 0.00
Ability of the technology to protect the individuals’ religion 0.75 0.75
Impact of the procedure on the social costs 0.67 0.50
T2DM individuals and citizens can have a good level of 
understanding of technology
1.08 1.00
Impact of the technology on the individual’s perceived quality of life 1.33 2.17
Impact of the technology on the care giver’s life and perception. 0.83 1.50
Average value for ethical and social impact 1.12 1.20
Legal Impact Traditional Instruments – 
“AS IS” Scenario
Traditional instruments + GA – 
“TO BE” Scenario
Permission level of technology 0.80 0.10
Need for inclusion of the technology in registry 0.00 0.00
Fulfilment of the safety requirements 1.80 1.70
Production warranties 1.80 1.80
Price control 0.90 −0.20
Infringement of intellectual property rights 0.00 0.10
The need to regulate the acquisition of technology 0.20 −0.60
The legislation covers the regulation of technology for all 
categories of individuals
0.50 −0.60
Average value for legal impact 0.75 0.29
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implementation could be absorbed within the first year 
after its introduction, thus also leading to economic advan-
tages related to the optimisation of the clinical pathway of 
T2DM insulin-naïve individuals, treated with oral thera-
pies. This economic advantage could therefore be variable 
from a minimum of 1.06% to a maximum of 4.58%, 
strictly dependent on the number of people with diabetes 
requiring a therapeutic switch.
On the other hand, higher perceptions regarding the 
ethical and social profile of GA introduction emerged: it 
would improve the quality of life of both individuals with 
diabetes and the related caregivers, as it is related with 
better monitoring of blood glucose and a lower risk of 
complications. According to the above, a topic for further 
research could be represented by the integration of the 
HTA results, especially referring to the social dimensions, 
with specific patient-reported outcome measures 
(PROMs), thus investigating the level of diabetes distress 
perceived by people living with this chronic disease.
The main strength of the present study is that it pro-
vides a “real-life” picture of the potential implications of 
GA in the Italian clinical practice, thus giving an over-
view of the modification of the patient clinical pathway, 
with a consequent economic resources absorption estima-
tion. It should be noted that, even though results could be 
influenced by Italian local issues, the clinical pathway is 
consistent with the International Guidelines on the topic, 
with regard to the exams and procedures devoted to peo-
ple with diabetes, being, thus, generalizable. The only 
pattern that could change worldwide, is the economic 
Table 5 Organisational Impact
Organisational Impact Short-Term (12 Months) Long-Term (12 Months)
Traditional 
Instruments – “AS 
IS” Scenario
Traditional Instruments 
+ GA – “TO BE” 
Scenario
Traditional 
Instruments – “AS 
IS” Scenario
Traditional Instruments 
+ GA – “TO BE” 
Scenario
Additional staff −0.20 −0.20 0.00 0.00
Training course 0.10 −0.80 0.00 0.20
Training for individuals and 
caregivers
−0.10 −0.70 −0.20 −0.20
Hospital meetings −0.10 −0.80 0.00 0.00
Learning curve 0.10 0.20 0.00 −0.10
Additional room space 0.00 0.00 0.00 0.00
Additional furniture 0.00 0.00 0.00 0.00
Additional equipment 0.00 −0.20 0.00 0.00
Equipment update 0.00 −0.50 0.00 −0.10
Purchase of equipment −0.10 −0.50 0.00 −0.10
Impact of the technology on 
internal processes
0.00 −0.50 0.10 0.90
Impact of the technology on 
purchasing processes
−0.10 −0.90 0.00 −0.10
Impact of the technology on 
hospital processes
0.10 0.20 0.10 1.40
Impact of the technology on the 
T2DM individual’s clinical 
pathway
0.10 0.90 0.20 2.30
Average Value −0.01 −0.27 0.01 0.30
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evaluation of the single item of healthcare expenditure (in 
terms of tariffs and prices), even if the economic dimen-
sion, on the whole, could be replicable within both NHS- 
based and insurance-based Countries, as demonstrated in 
the sensitivity analysis, confirming the robustness of the 
results.
Although GA has been studied over the last few years, 
this in-vitro diagnostic test is not yet widely used in the 
European clinical laboratory routine, and few commercial 
products are yet available on the market for this test, thus 
requiring the need of a national and international consensus 
about clinical laboratory procedures and the clinical use of 
GA, and guaranteeing its inclusion in clinical laboratory 
routines. In particular, despite its proven clinical effective-
ness, GA test is not included in any Italian clinical guideline 
and/or algorithm, thus requiring an in-depth evaluation as 
already performed in other Asian Countries.20
However, the results of the study, according to an HTA 
approach useful to validate the implementation of any 
innovative technology, with the integration of clinical 
and managerial information, make GA a promising marker 
to use for glycaemic control in people with T2DM, thus 
showing the strategic relevance of GA, in the improve-
ment of the clinical pathway of individuals with diabetes, 
freeing-up NHS resources, for public and private sector, 
also ensuring a better equity and social profile for indivi-
duals with diabetes.
This could be consistent with scientific recommenda-
tion available on the topic, in fact both the American 
Diabetes Association (ADA) and the European 
Association Diabetes Study (EASD) suggests a “patient- 
centred” management of glycemic control in T2DM indi-
viduals, and the selection only of biomarkers, such as GA, 
that could be able to reflect the individual health status, 
maintaining the balance between risks and benefits.9
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